Last reviewed · How we verify
Administration of quetiapine XR
Administration of quetiapine XR is a Atypical antipsychotic Small molecule drug developed by Tri-Service General Hospital. It is currently in Phase 3 development for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Bipolar depression.
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Bipolar depression.
At a glance
| Generic name | Administration of quetiapine XR |
|---|---|
| Sponsor | Tri-Service General Hospital |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Quetiapine blocks dopamine and serotonin receptors, reducing abnormal neurotransmitter activity associated with psychotic symptoms and mood disturbances. The extended-release (XR) formulation provides sustained drug delivery over 24 hours, improving medication adherence and maintaining steady-state plasma concentrations.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
- Bipolar depression
- Adjunctive treatment of major depressive disorder
Common side effects
- Somnolence/sedation
- Dry mouth
- Dizziness
- Weight gain
- Headache
- Constipation
- Tachycardia
Key clinical trials
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (PHASE4)
- Quetiapine for Bipolar Disorder and Alcohol Dependence (PHASE4)
- A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (PHASE3)
- Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression (PHASE4)
- Pioglitazone and Quetiapine XR Pharmacogenetic Study
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder (PHASE1)
- Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of quetiapine XR CI brief — competitive landscape report
- Administration of quetiapine XR updates RSS · CI watch RSS
- Tri-Service General Hospital portfolio CI
Frequently asked questions about Administration of quetiapine XR
What is Administration of quetiapine XR?
How does Administration of quetiapine XR work?
What is Administration of quetiapine XR used for?
Who makes Administration of quetiapine XR?
What drug class is Administration of quetiapine XR in?
What development phase is Administration of quetiapine XR in?
What are the side effects of Administration of quetiapine XR?
What does Administration of quetiapine XR target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Serotonin 5-HT2A receptor
- Manufacturer: Tri-Service General Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar I disorder (acute manic or mixed episodes)
- Indication: Drugs for Bipolar depression
- Compare: Administration of quetiapine XR vs similar drugs
- Pricing: Administration of quetiapine XR cost, discount & access